Similarly, CD9-targeting antibodies have been investigated as anti-cancer agents in different types of tumors (reviewed in [16]) and CD9 has been proposed as a therapeutic target in gastrointestinal cancer [41]. This evidence concerns the gene CD9 and cancer.